Vaxcyte, Inc. (PCVX): Cash & Equivalents
$173.96M
As of 2025-12-31
$183.19M
As of 2026-06-30
-40.7%
3-year compound annual growth
-14.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $173.96M | -55.2% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $387.88M | -2.4% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $397.45M | -52.4% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $834.66M | n/m | 2025-02-25, Balance as of period end |
| 2021-12-31 | $68.98M | -82.1% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $386.20M | +554.8% | 2023-02-27, Balance as of period end |
| 2019-12-31 | $58.98M | n/a | 2022-02-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | 2025-12-31 | $173.96M | -55.2% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| Revolution Medicines, Inc. (RVMD) | 2025-12-31 | $383.75M | -29.3% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $347.56M | +16.5% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $357.01M | +196.9% |
Compare PCVX, RGEN, EXEL, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗